March 22, 2006

For Immediate Release

Emerging Technologies and Worldwide Markets in Diabetes Management

FOOTHILL RANCH, CA According to a new report from MedMarket Diligence (MMD), diabetes management is facing the emergence of multiple new technologies, from marginal improvement (lancing devices, continuous monitoring, new insulin and antidiabetic drug formulations) to radical shifts (optical glucose sensors, closed-loop monitor/pump systems, stem cells, artificial pancreas).  A large marketplace with many competitors and sectors serve the needs of a growing patient population as the large, undiagnosed Type 2 population is steadily penetrated and as other forces (e.g., obesity) continue to drive incidence upward.

"With over 40 million patients in the U.S., Western Europe and Japan alone, the worldwide market for products in diabetes management exceeds $24 billion annually," notes Patrick Driscoll of MMD.  In addition, the chronic nature of diabetes makes for a stable treatment and monitoring market, says Driscoll. "But demand remains very high for improvement in the management of diabetes and this results in an aggressively innovative environment in which many technologies are now poised to succeed."

The MMD report details the worldwide incidence and prevalence by country/region of Type 1 and Type 2 diabetes and details the current and projected market for diagnostic and therapeutic products in the management of diabetes, including anti-diabetic drugs, alternative insulin types, blood glucose monitoring (including continuous monitoring devices), insulin pumps, and other established and emerging products in diabetes management.  The Worldwide Diabetes Management Market report is detailed here.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the MedMarkets newsletter, a monthly analysis of the market implications of new medical technologies, and dedicated reports on technology markets.  For additional details, contact Patrick Driscoll at email or call 949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.